MA44721B1 - Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer - Google Patents
Inhibiteurs de mcl1 macrocycliques pour le traitement du cancerInfo
- Publication number
- MA44721B1 MA44721B1 MA44721A MA44721A MA44721B1 MA 44721 B1 MA44721 B1 MA 44721B1 MA 44721 A MA44721 A MA 44721A MA 44721 A MA44721 A MA 44721A MA 44721 B1 MA44721 B1 MA 44721B1
- Authority
- MA
- Morocco
- Prior art keywords
- macrocyclic
- cancer treatment
- acid
- mcl1 inhibitors
- pentaazaheptacyclo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150094281 mcl1 gene Proteins 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un composé qui est l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique (formule 1), des énantiomères et des sels pharmaceutiquement acceptables correspondants. L'invention concerne également des compositions pharmaceutiques de l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique, et des énantiomères et des sels pharmaceutiquement acceptables correspondants, et des méthodes de traitement du cancer avec ces composés et ces compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (fr) | 2016-04-22 | 2017-04-21 | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44721A MA44721A (fr) | 2019-02-27 |
| MA44721B1 true MA44721B1 (fr) | 2020-05-29 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44721A MA44721B1 (fr) | 2016-04-22 | 2017-04-21 | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (fr) |
| EP (1) | EP3445767B1 (fr) |
| JP (1) | JP6894449B2 (fr) |
| KR (1) | KR102388208B1 (fr) |
| CN (1) | CN109071566B (fr) |
| AR (1) | AR108301A1 (fr) |
| AU (1) | AU2017252222B2 (fr) |
| BR (1) | BR112018070677B1 (fr) |
| CL (1) | CL2018002410A1 (fr) |
| CO (1) | CO2018008759A2 (fr) |
| CR (1) | CR20180499A (fr) |
| CY (1) | CY1123186T1 (fr) |
| DK (1) | DK3445767T3 (fr) |
| DO (1) | DOP2018000222A (fr) |
| EA (1) | EA036551B1 (fr) |
| ES (1) | ES2791319T3 (fr) |
| HR (1) | HRP20200673T1 (fr) |
| HU (1) | HUE049591T2 (fr) |
| IL (1) | IL262237B (fr) |
| LT (1) | LT3445767T (fr) |
| MA (1) | MA44721B1 (fr) |
| ME (1) | ME03729B (fr) |
| MX (1) | MX386103B (fr) |
| NI (1) | NI201800093A (fr) |
| PE (1) | PE20181803A1 (fr) |
| PH (1) | PH12018502227A1 (fr) |
| PL (1) | PL3445767T3 (fr) |
| PT (1) | PT3445767T (fr) |
| RS (1) | RS60257B1 (fr) |
| SG (1) | SG11201805838UA (fr) |
| SI (1) | SI3445767T1 (fr) |
| SM (1) | SMT202000249T1 (fr) |
| SV (1) | SV2018005742A (fr) |
| TN (1) | TN2018000319A1 (fr) |
| TW (1) | TWI742074B (fr) |
| WO (1) | WO2017182625A1 (fr) |
| ZA (1) | ZA201807766B (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10774110B2 (en) | 2016-02-04 | 2020-09-15 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| CA3013783A1 (fr) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapaglutines : nouveaux inhibiteurs de glut, et leur utilisation |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| PT3445767T (pt) | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
| US10981932B2 (en) | 2016-05-19 | 2021-04-20 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| CN111818917A (zh) | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| AR113886A1 (es) | 2017-11-17 | 2020-06-24 | Broad Inst Inc | Derivados de indol macrocíclicos |
| WO2019096914A1 (fr) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Dérivés d'indole macrocycliques substitués par du chlore |
| EP3710447A1 (fr) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Dérivés d'indole macrocycliques annelés aryle |
| EP3710451A1 (fr) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Dérivés d'indole macrocycliques substitués |
| EP3710448A1 (fr) | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Dérivés d'indole substitués par du chlore macrocyclique |
| WO2019096909A1 (fr) * | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Dérivés d'indole macrocycliques substitués par du fluor utilisés en tant qu'inhibiteurs de mcl-1, destinés à être utilisés dans le traitement du cancer |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| WO2020063792A1 (fr) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Dérivé macrocyclique d'indole, son procédé de préparation et son application en médecine |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| CN112204036B (zh) * | 2019-01-23 | 2022-12-27 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大环稠合的吡唑 |
| MX2021010321A (es) * | 2019-03-08 | 2021-11-17 | Zeno Man Inc | Compuestos macrociclicos. |
| TW202104228A (zh) | 2019-04-11 | 2021-02-01 | 美商必治妥美雅史谷比公司 | 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物 |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| CR20210556A (es) | 2019-05-10 | 2021-12-17 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos |
| CN114127079A (zh) | 2019-05-17 | 2022-03-01 | 布罗德研究所有限公司 | 制备大环吲哚的方法 |
| KR20220024106A (ko) | 2019-05-20 | 2022-03-03 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| AU2020296918A1 (en) * | 2019-06-21 | 2022-02-17 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of MCL-1 |
| CN114096546A (zh) | 2019-07-09 | 2022-02-25 | 詹森药业有限公司 | 用作mcl-1抑制剂的大环螺环衍生物 |
| WO2021067405A1 (fr) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Composés neuroprotecteurs et leurs procédés d'utilisation |
| WO2021092061A1 (fr) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Polythérapie pour le traitement de maladies associées à la sénescence |
| WO2021092053A1 (fr) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Composés macrocycliques inhibiteurs de mcl-1 destinés à être utilisées dans la gestion clinique d'états pathologiques provoqués ou induits par des cellules sénescentes ainsi que dans le traitement du cancer |
| WO2021099580A1 (fr) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Dérivés de sulfonyle macrocycliques utilisés en tant qu'inhibiteurs de mcl-1 |
| BR112022009142A2 (pt) * | 2019-11-21 | 2022-07-26 | Janssen Pharmaceutica Nv | Derivados de indol macrocíclicos como inibidores de mcl-1 |
| JP2023510135A (ja) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | 大環状化合物 |
| KR20220143906A (ko) | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
| WO2021197295A1 (fr) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | Forme cristalline d'un dérivé macrocyclique d'indole et son procédé de préparation |
| BR112022024117A2 (pt) | 2020-05-29 | 2022-12-27 | Janssen Pharmaceutica Nv | Derivados de 7-pirazol-5-il-indol macrocíclico como inibidores de mcl-1 |
| KR20230027153A (ko) * | 2020-06-19 | 2023-02-27 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 n-연결된 마크로사이클릭 4-(피라졸-5-일)-인돌 유도체 |
| EP4168412A1 (fr) | 2020-06-19 | 2023-04-26 | JANSSEN Pharmaceutica NV | Dérivés de 7-(pyrazol-5-yl)-indole à liaison n en tant qu'inhibiteurs de mcl-1 |
| KR20230035621A (ko) | 2020-07-08 | 2023-03-14 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서 인돌 유도체를 함유하는 마크로사이클릭 에테르 |
| WO2022032284A1 (fr) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Composés macrocycliques |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| JP2023553719A (ja) | 2020-12-17 | 2023-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体 |
| WO2022171782A1 (fr) | 2021-02-12 | 2022-08-18 | Janssen Pharmaceutica Nv | Dérivés macrocycliques de 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate et 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate 1,3-pontés en tant qu'inhibiteurs de mcl-1 pour le traitement du cancer |
| WO2022251247A1 (fr) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Composés macrocycliques |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| EP4413165A1 (fr) | 2021-10-06 | 2024-08-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de prédiction et d'amélioration de l'efficacité d'une thérapie par inhibiteur de mcl-1 |
| CN120787162A (zh) | 2022-05-20 | 2025-10-14 | 诺华股份有限公司 | 抗肿瘤化合物的抗体-药物缀合物及其使用方法 |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| PL2379580T3 (pl) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| SG181900A1 (en) * | 2009-12-23 | 2012-08-30 | Ironwood Pharmaceuticals Inc | Crth2 modulators |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| US10005728B2 (en) | 2013-08-28 | 2018-06-26 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| WO2015123230A1 (fr) * | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Utilisation de macrocycles de benzothiazole comme qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| WO2015148854A1 (fr) | 2014-03-27 | 2015-10-01 | Vanderbilt University | Inhibiteurs de indole mcl-1 substitués |
| TN2016000435A1 (en) * | 2014-04-11 | 2018-04-04 | Bayer Pharma AG | Novel macrocyclic compounds. |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| PT3445767T (pt) | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
-
2017
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/fr active Active
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/fr not_active Ceased
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/fr unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44721B1 (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA47102B1 (fr) | Dérivés de pyrane en tant qu'inhibiteurs de cyp11a1 (cytochrome p450 monooxygénase 11a1) | |
| WO2018125961A8 (fr) | Inhibiteurs de la poly-adp-ribose polymérase (parp) | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| EP4252848A3 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| EA201990904A1 (ru) | 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA38922A3 (fr) | Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih | |
| TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MY207239A (en) | Imidazopyridinone compound | |
| MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle |